A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : TN / treatment-naive

[Related PubMed/MEDLINE]
Total Number of Papers: 53
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   TN  (>> Co-occurring Abbreviation)
Long Form:   treatment-naive
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients. CLL, FISH, TTFT
2019 Cost Effectiveness of Avelumab for Metastatic Merkel Cell Carcinoma. mMCC, QALYs, SC, TE
2019 Cost-effectiveness analysis of sofosbuvir plus ribavirin in patients with genotype 2 chronic hepatitis C: an analysis with real world outcomes from a multicentre cohort in Japan. CC, DC, GT, HCC, ICERs, IFN, LT, NC, QALY, SVR, TE, TVR
2019 Direct-acting antiviral Therapy Is Safe and Effective in Pediatric Chronic Hepatitis C: The Public Health Perspective. CHC, DAAs, DCV, SOF, SVR, SVR12, TE
2019 Effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir for HCV in HIV/HCV coinfected subjects: a comprehensive analysis. AEs, GT, HCV, HIV, OBV, PTV, SAEs, SVR12, TE
2019 Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL. CLL, ORR
2019 Ibrutinib induces chromatin reorganisation of chronic lymphocytic leukaemia cells. BTK, CLL
2019 Immunosuppressive therapy (IST) in adult patients with acquired aplastic anemia (AA): A single-center experience over the past 15 years. AA, ARC, h-ATG, IST, pts, R/R, rATG, RRs
2019 New resistance mutations to nucleoside reverse transcriptase inhibitors at codon 184 of HIV-1 reverse transcriptase (M184L and M184T). MDS, NRTI, RT, TE
10  2019 Ofatumumab plus high dose methylprednisolone followed by ofatumumab plus alemtuzumab to achieve maximal cytoreduction prior to allogeneic transplantation for 17p deleted or TP53 mutated chronic lymphocytic leukemia. CLL, MRD, R/R
11  2019 Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis. AEs, CLL, ORR, OS, PFS, R/R
12  2019 Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments. CLL, FDR, R/R
13  2018 Cost-effectiveness of dolutegravir/abacavir/lamivudine in HIV-1 treatment-Naive (TN) patients in France. ABC, DTG, INI, PIs
14  2018 Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study. CLL, MRD, OS, PFS, RR
15  2018 Duvelisib, an oral dual PI3K-delta,gamma inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study. CLL, PI3K, RR, SLL
16  2018 Single-agent ibrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. CLL/SLL, PFS, R/R
17  2018 Tolerability and discontinuation rates in teriflunomide-treated patients. A real-world clinical experience. MS, PT
18  2017 Clinical outcomes in adult patients with aplastic anemia: A single institution experience. AA, IST, OS, R/R, RFS
19  2017 Cost-Utility of Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1 Infection. EBR/GZR, GT, LDV/SOF, SOF/VEL
20  2017 Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. CLL/SLL, PFS, R/R
21  2017 Outcomes of treatment with direct-acting antivirals for infection with hepatitis C virus genotypes 1-4 in an ambulatory care setting. DAAs, EMR, HCV, SVR, TE
22  2017 Phase 3 trial of first generation protease inhibitor therapy for hepatitis C virus/human immunodeficiency virus coinfection. HCV, PEG-IFN, RBV, SVR, TE
23  2017 Treatment Stage Migration Maximizes Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib: An Observational Study. BCLC, CP, OS, PT
24  2016 Boceprevir plus peginterferon/ribavirin for treatment of chronic hepatitis C in Russia. HCV, PR, SVR, TE, TW8
25  2016 Extra-hepatic infection of hepatitis C virus in the colon tissue and its relationship with hepatitis C virus pathogenesis. CHC, HCV, NR, SVR, Treg
26  2016 Metabolic consequences of acute and chronic empagliflozin administration in treatment-naive and metformin pretreated patients with type 2 diabetes. EGP, Met, SGLT2
27  2015 Association of colonic regulatory T cells with hepatitis C virus pathogenesis and liver pathology. CHC, FoxP3, HCV, IL, NR, SVR, Treg
28  2015 Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Naive and Treatment-Experienced Patients in Canada. ARAMIS, DTG, EFV, HIV, RAL, RPV, TE
29  2015 Cost-effectiveness of sofosbuvir plus ribavirin with or without pegylated interferon for the treatment of chronic hepatitis C in Italy. GT, HCV, ICERs, PEG-INF, RBV, SVR, UI
30  2015 Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis. BOC, ITT, mITT, NR, PIs, PR, SVR, TE, TVR
31  2015 HIV economic burden of illness in the Veterans Health Administration population. ART, HIV, ICD-9-CM, NNRTI, PSM, VHA
32  2015 Nevirapine-related adverse events among children switched from efavirenz to nevirapine as compared to children who were started on nevirapine-based antiretroviral therapy directly. EFV, NVP, TE
33  2014 A significant reduction in the frequency of HIV-1 drug resistance in Quebec from 2001 to 2011 is associated with a decrease in the monitored viral load. TE, VL
34  2014 Bone quality of the newest bone formed after two years of teriparatide therapy in patients who were previously treatment-naive or on long-term alendronate therapy. ALN, M/M, MMC, PG, TPTD
35  2014 Burden of nonnucleoside reverse transcriptase inhibitor resistance in HIV-1-infected patients: a systematic review and meta-analysis. EU, NNRTI, TE, US
36  2014 Cost utility of telaprevir-PR (peginterferon-ribavirin) versus boceprevir-PR and versus PR alone in chronic hepatitis C in The Netherlands. BPR, MTC, PR, QALYs, SVR, TE, TPR
37  2014 Effects of teriparatide on cortical histomorphometric variables in postmenopausal women with or without prior alendronate treatment. ALN, MAR
38  2014 Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. HCV, LDV, RBV, SOF, SVR12
39  2014 High Molecular Weight (HMW): total adiponectin ratio is low in hiv-infected women receiving protease inhibitors. HAART, HMW, NRTIs, PI, TA, WHR
40  2014 Treatment failure may lead to accelerated fibrosis progression in patients with chronic hepatitis C. CHC, FPR, GGT, SFP, TF
41  2013 Antiviral effect, safety, and pharmacokinetics of five-day oral administration of Deleobuvir (BI 207127), an investigational hepatitis C virus RNA polymerase inhibitor, in patients with chronic hepatitis C. AEs, HCV, TE
42  2012 Mutational patterns in the frameshift-regulating site of HIV-1 selected by protease inhibitors. PI-R
43  2012 Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin. AEs, GT, HCV, RVR, RVR, TE, TID
44  2012 The epidemiology and clinical correlates of HIV-1 co-receptor tropism in non-subtype B infections from India, Uganda and South Africa. CCR5, TE, TE
45  2011 A multicenter study of the predictors of adherence to self-injected glatiramer acetate for treatment of relapsing-remitting multiple sclerosis. RRMS, TE
46  2011 Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study. HCV, NR
47  2010 Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis. Ac.f, ALN, OS
48  2008 Executive functioning in children with attention-deficit/hyperactivity disorder: combined type with and without a stimulant medication history. ADHD, LD
49  2007 Clinical responders to antiviral therapy of chronic HCV infection show elevated antiviral CD4+ and CD8+ T-cell responses. HCV, NRs
50  2007 Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis. ALN, Cr.Dn, Cr.S.Dn
51  2005 Low density lipoprotein apolipoprotein B metabolism in treatment-naive HIV patients and patients on antiretroviral therapy. apoB, ASR, FCR, LDL, NNRTI, PI, RT, RTV
52  2004 Efficacy and tolerability of initial combination therapy with nateglinide and metformin in treatment-naive patients with type 2 diabetes. CT, FPG, PPGE, T2DM
53  2004 Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group. CI, HAART, PYFU, TCF, TE